1312438-49-5

Upstream product

• 1312438-79-1 1,5-dimethyl (R,S)-2-{[(4-methylbenzene)sulfonyl]oxy}-4-methylidenepentanedioate 
• 1312438-46-2 dimethyl (2RS,4R)-2-{[bis(benzyloxy)phosphoryl]methyl}-4-(tosyloxy)pentanedioate 
• 1312438-44-0 dimethyl rac-2-{[bis(benzyloxy)phosphoryl]methyl}-4-(tosyloxy)pentanedioate 
• 1312438-70-2 dimethyl 2-hydroxy-4-methylenepentanedioate 
• 1312438-85-9 dimethyl (2RS,4R)-2-{[bis(benzyloxy)phosphoryl]methyl}-4-{[tert-butyl(dimethyl)silyl]oxy}pentanedioate 
• 1312438-77-9 dimethyl rac-2-{[bis(benzyloxy)phosphoryl]methyl}-4-[(3,4,5,6-tetrahydro-2H-pyran-2-yl)oxy]pentanedioate 
• 1312438-76-8 dimethyl rac-2-methylene-4-[(3,4,5,6-tetrahydro-2H-pyran-2-yl)oxy]pentanedioate 
• 4224-69-5 methyl 2-(bromomethyl)propenoate 
• 1312438-88-2 dimethyl (2S,4R)-2-{[bis(benzyloxy)phosphoryl]methyl}-4-{[tert-butyl(dimethyl)silyl]oxy}pentanedioate 
• 4124-41-8 p-toluenesulfonylanhydride 

Downstream Products

• 1312438-59-7 dimethyl (2S,4S)-2-{[bis(benzyloxy)phosphoryl]methyl}-4-fluoropentanedioate 

Relevant academic research and scientific papers

DERIVATIZATION OF RADIOPHARMACEUTICALS

This invention relates to methods for analyzing radiopharmaceuticals wherein the radiopharmaceutical is derivatized beforehand. This method is suitable for compounds labeled with radioisotope or with cold counterpart e.g. 18F or 19F,

PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS

This invention relates to novel compounds suitable for labelling by 18F and the corresponding 18F labelled compounds themselves, 19F-fluorinated analogues thereof and their use as reference standards, methods of preparing